GB202104635D0 - Methods and compositions for identifying and treating GCN2-dependent cancers - Google Patents

Methods and compositions for identifying and treating GCN2-dependent cancers

Info

Publication number
GB202104635D0
GB202104635D0 GBGB2104635.4A GB202104635A GB202104635D0 GB 202104635 D0 GB202104635 D0 GB 202104635D0 GB 202104635 A GB202104635 A GB 202104635A GB 202104635 D0 GB202104635 D0 GB 202104635D0
Authority
GB
United Kingdom
Prior art keywords
gcn2
identifying
compositions
treating
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2104635.4A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ip2ipo Innovations Ltd
Original Assignee
Imperial College Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial College Innovations Ltd filed Critical Imperial College Innovations Ltd
Priority to GBGB2104635.4A priority Critical patent/GB202104635D0/en
Publication of GB202104635D0 publication Critical patent/GB202104635D0/en
Priority to PCT/GB2022/050825 priority patent/WO2022208107A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
GBGB2104635.4A 2021-03-31 2021-03-31 Methods and compositions for identifying and treating GCN2-dependent cancers Ceased GB202104635D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2104635.4A GB202104635D0 (en) 2021-03-31 2021-03-31 Methods and compositions for identifying and treating GCN2-dependent cancers
PCT/GB2022/050825 WO2022208107A1 (en) 2021-03-31 2022-03-31 Methods and compositions for identifying and treating gcn2-dependent cancers

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2104635.4A GB202104635D0 (en) 2021-03-31 2021-03-31 Methods and compositions for identifying and treating GCN2-dependent cancers

Publications (1)

Publication Number Publication Date
GB202104635D0 true GB202104635D0 (en) 2021-05-12

Family

ID=75783639

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2104635.4A Ceased GB202104635D0 (en) 2021-03-31 2021-03-31 Methods and compositions for identifying and treating GCN2-dependent cancers

Country Status (2)

Country Link
GB (1) GB202104635D0 (en)
WO (1) WO2022208107A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018030466A1 (en) 2016-08-10 2018-02-15 武田薬品工業株式会社 Heterocyclic compound
US20190233411A1 (en) 2018-01-29 2019-08-01 Merck Patent Gmbh Gcn2 inhibitors and uses thereof
US20190233425A1 (en) 2018-01-29 2019-08-01 Merck Patent Gmbh Gcn2 inhibitors and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10648983B2 (en) * 2016-01-08 2020-05-12 Celgene Corporation Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies
WO2018024608A2 (en) * 2016-08-03 2018-02-08 Cbmed Gmbh Center For Biomarker Research In Medicine Antitumor compounds and tumor diagnosis
GB202008749D0 (en) 2020-06-09 2020-07-22 Ip2Ipo Innovations Ltd Novel compounds
CN112522401B (en) * 2020-11-16 2021-09-24 北京大学人民医院 Application of TOX3 gene overexpression as liver cancer prognosis marker

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018030466A1 (en) 2016-08-10 2018-02-15 武田薬品工業株式会社 Heterocyclic compound
US20190233411A1 (en) 2018-01-29 2019-08-01 Merck Patent Gmbh Gcn2 inhibitors and uses thereof
US20190233425A1 (en) 2018-01-29 2019-08-01 Merck Patent Gmbh Gcn2 inhibitors and uses thereof

Non-Patent Citations (35)

* Cited by examiner, † Cited by third party
Title
BRAZEAUROSSE, ACS MED CHEM LETT., vol. 5, no. 4, 2014, pages 282 - 283
CIARDIELLO ET AL., ANNALS OF ONCOLOGY, vol. 31, no. 10, 2020, pages 1336 - 1349
DONG ET AL., MOL CELL, vol. 6, 2000, pages 269 - 279
DONG ET AL., MOLECULAR CELL, vol. 6, 2000, pages 269 - 279
DURINCK ET AL.: "BioMart and Bioconductor: a powerful link between biological databases and microarray data analysis", BIOINFORMATICS, vol. 21, 2005, pages 3439 - 3440
FRIEDMAN ET AL., J STAT SOFTW, vol. 33, 2010, pages 1 - 22
FUJIMOTO, J. ET AL., ACS MED. CHEM. LETT., vol. 10, no. 1, 2019, pages 1498 - 1503
GARLAND, CURRENT BIOLOGY, vol. 24, 2014, pages R60 - 61
GU ET AL., BIOINFORMATICS, vol. 32, 2016, pages 2847 - 2849
HANAHANWEINBERG, CELL, vol. 144, 2011, pages 646 - 674
HANZELMANN ET AL., BMC BIOINFORMATICS, vol. 14, no. 7, 2013
HARDING ET AL., MOL CELL, vol. 11, 2003, pages 619 - 633
HARDING ET AL., MOLECULAR CELL, vol. 11, 2003, pages 619 - 633
HUYNH ET AL., BIOMOLECULES, vol. 9, no. 11, 2019, pages 743
JAIN ET AL., SCIENCE, vol. 336, 2012, pages 1040 - 1044
KATO ET AL., MOL. PHARM., vol. 98, no. 6, 2020, pages 669 - 676
LISTANMORE, COLD SPRING HARBOR PROTOCOLS, 2019
LOAIZA ET AL., BIOMATERIALS, vol. 183, 2018, pages 102 - 113
LOVE ET AL., GENOME BIOL, vol. 15, 2014, pages 550
LU ET AL., J. BIOMED. SCI., vol. 27, no. 1, 2020, Retrieved from the Internet <URL:http://doi.org/10.1186/s12929-019-0592>
M. E. RITCHIE ET AL.: "limma powers differential expression analyses for RNA-sequencing and microarray studies", NUCLEIC ACIDS RES, vol. 43, 2015, pages e47
MOREAU ET AL., BLOOD, vol. 120, 2012, pages 947 - 959
NAKAMURA ET AL., PNAS, vol. 115, no. 33, 2018, pages E7776 - E7785
NATURE GENETICS, vol. 49, no. 12, pages 1779 - 1784
OBENG ET AL., BLOOD, vol. 107, 2006, pages 4907 - 4916
OU ET AL., J CLIN PHARMACOL, vol. 57, 2017, pages 663 - 677
PAPADOPOULOS ET AL., J CLIN ONCOL, vol. 33, 2015, pages 732 - 739
PARZYCH ET AL., ONCOGENE, vol. 38, 2019, pages 3216 - 3231
PETROVA ET AL., ONCOGENESIS, vol. 7, 2018, pages 10
POUYSSEGUR ET AL., NATURE, vol. 441, 2006, pages 437 - 443
RIO ET AL.: "RNA: A Laboratory Manual", 2011, COLD SPRING HARBOR LABORATORY PRESS
S. DURINCKP. T. SPELLMANE. BIRNEYW. HUBER: "Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt", NAT PROTOC, vol. 4, 2009, pages 1184 - 1191
SAAVEDRA-GARCIA ET AL., AMERICAN JOURNAL OF PHYSIOLOGY: CELL PHYSIOLOGY, vol. 318, 2020, pages C451 - C462
SHAUGHNESSY, JR. ET AL., BLOOD, vol. 118, 2011, pages 3512 - 3524
SONESON ET AL., FLOOORES, vol. 4, 2015, pages 1521

Also Published As

Publication number Publication date
WO2022208107A1 (en) 2022-10-06

Similar Documents

Publication Publication Date Title
IL288914A (en) Compositions and methods for treating cancer
IL286350A (en) Compositions and methods for treating cancer
EP4149547A4 (en) Compositions and methods for treating cancer
ZA202104870B (en) Methods and compositions for treating cancer
IL300067A (en) Compositions and methods for treatment of cancers
IL287982A (en) Compositions and methods for treating cancer
EP4097486A4 (en) Compositions and methods for treating ceacam positive cancers
SG11202109336UA (en) Methods and compositions for treating cancer
IL285886A (en) Compositions and methods for treating laminopathies
EP4110822A4 (en) Compositions and methods for treating cancer
IL286153A (en) Methods and compositions for treating cancer
EP4100028A4 (en) Compositions and methods for treating mesothelin positive cancers
IL309662A (en) Compositions and methods for treating cancers
EP4127722A4 (en) Methods and compositions for treating cancer
IL312846A (en) Methods and compositions for treating cancer
IL312844A (en) Methods and compositions for treating cancer
EP3959199A4 (en) Compositions and methods for treating ras-mutant cancers
IL309120A (en) Methods and compositions for treating cancer
IL309071A (en) Methods and compositions for treating cancer
IL304400A (en) Compositions and methods for preventing tumors and cancer
PT4058474T (en) Compositions and methods for treating egfr positive cancers
EP4149508A4 (en) Compositions and methods for treating cancer
EP4243835A4 (en) Compositions and methods for treating solid cancer
EP4118122A4 (en) Methods and compositions for identifying and treating glutaminase inhibitor-sensitive cancers
IL285036A (en) Methods and compositions for treating cancer

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)